A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough

Study ID: 4329
NCT Number: NCT06504446
Principal Investigator: Christine Franzese, MD
Department: Otolaryngology
Eligibility: Both men and women 18 years old to 80 years old. Does not accept healthy volunteers.